AstraZeneca Stock Skyrockets: The Unstoppable Rally Defying Market Gravity

AstraZeneca shares are mooning while traditional markets flatline—pharma's latest pump has analysts scrambling for explanations.

The catalyst? Big Pharma plays its oldest trick.

Behind every double-digit stock surge lies either genuine innovation or financial engineering. AstraZeneca's pipeline announcements today triggered the algo-trading equivalent of a FOMO stampede.

Short sellers got rekt (again).

While retail investors chase the green candles, institutional players quietly accumulate positions—because nothing beats a regulated monopoly with patent protection. The stock's RSI screams overbought, but fundamentals haven't mattered since 2020.

Another day, another pharma stock outperforming Bitcoin. At least crypto never pretended to care about your health.

Double-digit improvements

AstraZeneca, which is headquartered in the U.K. but reports its financials in U.S. dollars, earned just under $14.5 billion in its second quarter. That was a robust 12% higher year over year, and beat the consensus analyst estimate of slightly below $14.1 billion.

Image source: Getty Images.

Profitability also ROSE at a double-digit percentage rate. The company's "core" (non-GAAP, or adjusted) net income came in at just under $3.4 billion. In per-share terms, this was $2.17, a figure 10% higher than in the same period of 2024. This blew past the average pundit projection of $1.09.

AstraZeneca attributed its notably higher revenue to strong growth in sales of oncology drugs and biopharmaceuticals. Taking a peek into the future, the company also said it recorded 12 positive phase 3 clinical trial readouts of drugs in development.

A pledge to nearly double revenue within a few years

Speaking of periods to come, AstraZeneca reiterated its guidance for the entirety of 2025. Management believes it will be able to boost revenue, at constant exchange rates, in the high single digit percentages compared to full-year 2024. The company also reaffirmed its commitment to reaching annual revenue of $80 billion by 2030; last year's top line reached just over $42 billion.

Meanwhile, Core net earnings are forecast to rise at a low double-digit percentage rate. AstraZeneca did not get more specific.